{"id":8120,"date":"2024-01-21T04:57:23","date_gmt":"2024-01-20T23:27:23","guid":{"rendered":"https:\/\/indianpharmanetwork.co.in\/medicines\/?post_type=product&p=8120"},"modified":"2024-10-04T17:07:54","modified_gmt":"2024-10-04T11:37:54","slug":"scemblix-price-india","status":"publish","type":"product","link":"https:\/\/indianpharmanetwork.co.in\/medicines\/product\/scemblix-price-india\/","title":{"rendered":"SCEMBLIX (asciminib) Tablets"},"content":{"rendered":"

Generic Name: asciminib Brand Name: SCEMBLIX<\/strong>
\nSCEMBLIX (asciminib) tablets is a prescription medicine used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).<\/h4>\n

What asciminib is and used for?<\/h4>\n

Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.
\nAsciminib was approved for medical use in the United States in October 2021, and in the European Union in August 2022. The U.S. Food and Drug Administration (FDA) granted the application for asciminib priority review, fast track, orphan drug, and breakthrough therapy designations.
\nAsciminib is described as a “STAMP inhibitor,” which means “specifically targeting the ABL myristoyl pocket.” The wild-type ABL has a myristoylated N-terminus, which binds to an allosteric site, but the ABL fusion protein does not have the myristoylated domain. In the wild-type protein, when myristoylated N-terminus binds to the allosteric site, the kinase has reduced activity. Since the mutant fusion protein does not have the myristoylated N-terminus domain, it is not subject to this form of regulation, and thus the fusion protein is constitutively active. Asciminib binds to the allosteric site, resulting in an inhibition of bcr-abl activity.<\/p>\n

How can 1 go about obtaining SCEMBLIX Tablets?<\/h4>\n

If SCEMBLIX (asciminib) Tablets\u00a0<\/strong>are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n

Note:<\/strong>
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\n

NEWS \/ UPDATES<\/strong><\/p>\n